0000 |
Prevalence of AIDS-associated malignancies among HIV-infected parties in Ghana |
Washington University in St. Louis |
Prof. Kwadjo Koram |
1 year |
$8,500 |
0000 |
Implementation of a Handshake Stewardship Intervention to Address Perioperative Antibiotic Use at the University of Ghana Medical Center |
Washington University in St. Louis |
Prof. George Boateng Kyei |
1 year |
$21,670 |
0000 |
Impact of tuberculosis on the HIV reservoir |
National Institutes of Health |
Prof. George Boateng Kyei |
2 years |
$288,738 |
0000 |
Digital Health-Enabled Assessment of Pregnancy and Postpartum Physiologic changes. |
Google |
Prof. George Boateng Kyei & Prof. Samuel Oppong |
2 years |
$185,451 |
0000 |
Developing an Ethical Framework for the use of Artificial Intelligence for Cancer Care in Sub-Saharan Africa |
Conquer Cancer Foundation |
Dr. Erica Koranteng |
2 years |
$50,000 |
0000 |
HIV Basic Science and Cure Research Training for Scientists at the University of Ghana (H-Cure-RT) |
National Institutes of Health |
Prof. George Boateng Kyei |
5 years |
$681,430 |
0000 |
Multicentric study for assessing safety and clinical performance of Nanox.ARC in providing additional information to conventional two-dimensional (2D) radiography when evaluating adult individuals with known or suspected radiographic abnormalities |
Nanox Imaging |
Prof. George Boateng Kyei |
1 year |
$46,791 |
0000 |
Validating myo-inositol, a novel renal biomarker for kidney disease. |
Wellcome Trust |
Dr. Catherine Omosule |
5 years |
£580,785 (GBP) |
0000 |
Pharmacokinetics And Pharmacogenomics of Dolutegravir-Based Antiretroviral Therapy in Young People Living With HIV in Ghana (PHARMA-YOUNG-HIV) |
National Institutes of Health |
Dr. Ekow Thomford |
2 years |
$153,912 |
0000 |
Roczen Clinical Service Evaluation (CSE) |
Reset Health Clinics Limited |
Dr. Henrietta Norkai Ocran |
5 months |
$40,634.95 |
0000 |
Pfizer Antimicrobial Educational grant |
Pfizer Inc. |
Prof. George Boateng Kyei |
3 months |
$19,656 |
0000 |
Assessment of a novel fixed dose combination (FDC) drug VR-AD-1005 for the treatment of acute watery diarrhea in cholera: A phase II, multicenter, randomized, placebo controlled, double blinded efficacy and safety trial. |
Vanessa Research Holdings, Inc. |
Prof. Ernest Kenu |
N/A |
$20,000 |